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Summary 
Insulinomas are predominantly benign (~90%), pancreatic neuroendocrine tumours characterised by 
hyperinsulinaemic hypoglycaemia. They usually present as a small (<2cm), well demarcated, solitary 
nodule that can arise in any part of the organ. Treatment of sporadic insulinomas is generally aimed 
at curative surgical resection with special consideration in genetic syndromes. 
Patients with significant hypoglycaemia can pose a difficult management challenge. In isolated cases 
where the patient is not medically fit for surgery or with metastatic spread, other treatment options 
are employed. Medical therapy with diazoxide or somatostatin analogues are commonly used first-
line for symptom control, albeit with variable efficacy. Other medical options are emerging including 
newer targeted biological therapies, including everolimus (an mTOR inhibitor), sunitinib (a tyrosine 
kinase inhibitor) and pasireotide, a multi-somatostatin receptor ligand. Pasireotide and everolimus 
both cause hyperglycaemia by physiological mechanisms synergistic with its anti-tumour/anti-
proliferative effects. Minimally invasive treatment modalities such as ethanol ablation are available 
in selected cases (particularly in patients unfit for surgery), peptide receptor radionuclide therapy 
(PRRT) can effectively control tumour growth or provide symptomatic benefit in metastatic disease 
while cytotoxic chemotherapy can be used in patients with higher grade tumours.  
This review considers the developments in the medical and other non-surgical management options 
for cases refractory to standard medical management. Early referral to a dedicated neuroendocrine 
multidisciplinary team is critical considering the array of medical, oncological, interventional 
radiological and nuclear medical options. We discuss the evolving armamentarium for insulinomas 
when standard medical therapy fails. 
 
Keywords: Insulinoma, neuroendocrine tumours, pasireotide, everolimus, sunitinib, ablation, 
peptide receptor radionuclide therapy. 
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1. INTRODUCTION 
Insulinomas are rare, functioning pancreatic neuroendocrine tumours (pNETs), with an estimated 
incidence of 4 cases per million per year.[1] Insulinomas usually occur sporadically but in a small 
number of cases occur as part of an inherited syndrome, most commonly as a feature of multiple 
endocrine neoplasia type 1 (MEN-1) (<5%) and more rarely von Hippel-Lindau disease (VHL), 
neurofibromatosis 1 (NF-1) and tuberous sclerosis complex (TSC).[2] 
 
1.1 Diagnosis of insulinomas  
The presence of Whipple's triad: symptoms and signs of hypoglycemia with low plasma glucose 
levels, that are reversed by the administration of carbohydrate, are the characteristic diagnostic 
features. The evaluation and management of hypoglycaemia in patients with evidence of Whipple’s 
triad has been clearly described.[3] Hyperinsulinaemic hypoglycaemia should be suspected in an 
otherwise fit and well individual after exclusion of medication use (oral hypoglycaemic agents, 
insulin administration), factitious hypoglycaemia, non-insulinoma pancreatogenous hypoglycaemia 
and rarely non-islet cell tumours.[4] The most common cause of hyperinsulinaemic hypoglycaemia in 
adults is an insulinoma. Hypoglycaemia occurs primarily in the fasting state, although occasionally 
only in the post-prandial period, and can pose a significant management challenge and cause of 
morbidity.[5] 
 
1.2 Localisation of disease  
Having confirmed the biochemical diagnosis, localisation of disease can be challenging. Conventional 
imaging (i.e. CT/MRI) and, if available, endoscopic ultrasound form the basis of localisation and 
diagnosis of suspected insulinomas. 68Ga-DOTATATE PET-CT has a clear place in localising 
insulinomas because of the high affinity of the 68Ga-DOTA peptides for somatostatin receptors (a 10-
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fold higher affinity than 111In-Octreotide).[6] Glucagon-like peptide-1 receptors (GLP1-R) are also 
highly expressed in almost all benign insulinomas and so recently we have seen the application of 
68Ga-DOTA-exendin 4 PET-CT to facilitate the localisation of occult insulinomas.[7] In contrast, 
malignant insulinoma often lack these GLP1-R.[8] Once localised, surgical resection of sporadic 
insulinomas is standard treatment since most tumours are small (<2cm), benign and can be 
surgically cured however there is an associated high risk of complications and only limited patients 
may be eligible.[9]  
 
1.3 Classification of pNETs  
The management and prognosis of pNETs is governed by both the size, histological grade and 
disease staging.[10,11] For staging and grading of insulinomas, World Health Organization 
(WHO)[12], American Joint Committee on Cancer/Union for International Cancer Control 
(AJCC/UICC)[13] and European Neuroendocrine Tumour Society (ENETS)[14] guidelines for pNETs 
may be applied based on histological findings from tissue biopsy, size of tumour and extent of 
spread. The 2010 WHO classification sub-divides pNETs in three grades (G1, G2 and G3) on the basis 
of Ki-67 nuclear antigen expression (< 2%, 2%-20% and > 20%) and mitotic rate (< 2; 2-20 and > 20): 
G1 and G2 are referred to as NETs and G3 as neuroendocrine carcinomas (NECs).[12] Well and 
moderately differentiated NETs (G1/G2) have a significantly better survival compared to poorly 
differentiated neuroendocrine carcinomas (G3). According to the TNM classification, the tumour is 
classified as T1a (< 1 cm), T1b (1-2 cm) and T2 (larger than 2 cm); T3 and T4 are locally advanced 
tumours.[13]  
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2. THERAPEUTIC OPTIONS AVAILABLE FOR INSULINOMAS 
Recent consensus guidance has been published on the management of functional and non-
functional pNETs.[14-16] Based on the suspected aggressiveness of the disease, patients may be 
offered different treatment regimens (Figure 1). In insulinomas of genetic aetiology the clinical 
features may differ (e.g. earlier age of onset, multi-focal nature of disease, natural history) 
compared to sporadic insulinomas and this should be considered when considering treatment 
options.  
 
2.1. Surgery 
Surgery is the treatment of choice whenever possible. It provides both symptomatic control as well 
as long-term cure. In the presence of primary and well-differentiated metastatic functional pNETs, 
surgery with curative intent must always be considered, even if there is liver or lymph node 
involvement. For unresectable metastatic disease, the resection of the functional primary NET, like 
insulinomas, is controversial due to the marginal improvement in symptomatic control in this 
palliative setting, and the potential morbidities associated with the surgery. Despite this, studies 
have suggested that there could possibly be improvement of long term overall and progression free 
survival after primary tumour resection in this advanced stage.[17,18]  
 
2.2 Conventional advice and medical therapy  
Surgery remains the preferred treatment whenever possible, but prior to surgery or if surgery 
cannot be performed medical treatment is needed. Simple dietary modifications are explained to all 
patients involving frequent small carbohydrate-rich meals throughout the day and evening to avoid 
hypoglycaemia. There is currently no specific Driver and Vehicle Licensing Agency (DVLA) advice for 
drivers with an insulinoma, only for patients with type 1 or type 2 diabetes mellitus prone to 
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recurrent hypoglycaemic episodes. The patient should be advised to inform the DVLA of their 
diagnosis. 
 
2.3 Diazoxide 
Medical treatment is available to those who are unable or unwilling to undergo surgical treatment 
and as an adjunct to other treatment modalities. Diazoxide, an anti-hypertensive benzothiadiazine 
which acts as a potassium-channel activator, has formed the mainstay of medical management in 
symptomatic control of insulinomas for over 30 years.[19] Diazoxide is generally regarded as first-
line treatment for control of hypoglycaemia in patients with insulinomas, frequently used pre-
operatively when dietary and lifestyle advice fails to prevent hypoglycaemia. Potential glycaemic 
mechanisms include inhibition of insulin release by direct action on β-cells through stimulation of α-
adrenergic receptors[20] or increasing hepatic gluconeogenesis and reduced skeletal muscle glucose 
uptake.[21] Initiation doses of 50-300mg daily titrated to a maximum daily dose of 600mg (higher 
doses may be used in refractory hypoglycaemia) are used. Unfortunately side-effects are common 
(e.g. fluid retention, hirsutism, headache, gastrointestinal upset, rash) but usually not problematic 
and it offers symptom control in about 50-60% of patients.[22] Long term treatment appears to be 
safe. 
 
2.4 Somatostatin analogues (SSAs) 
Somatostatin, produced in the pancreatic -cells, acts as a paracrine regulator of insulin and 
glucagon secretion, and regulates cell proliferation, via interaction with five different (G-protein 
coupled) somatostatin receptors (SSTR1-5). These SSTR subtypes have distinct molecular structures, 
tissue distribution, intracellular signalling and pharmacological characteristics inhibiting different 
hormones. SSTR2 is the dominant receptor in both  cells (glucagon) and  cells (insulin).[23] 
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2.4.1 Octreotide and Lanreotide 
Inhibitory effect on hormone production by the tumour Synthetic SSAs have a unique binding affinity 
profile for each SSTR. These SSAs will suppress insulin and glucagon release from normal pancreatic 
cells via SSTR2. NETs in general often express SSTRs at high levels, with SSTR2 being the most 
prevalent subtype, while in contrast insulinomas have much lower SSTR2 expression. Octreotide and 
lanreotide have a preferential affinity for mainly SSTR2 and much less to SSTR5. This differential SSTR 
sub-type distribution explains the variable glycaemic response to SSAs treatment in insulinomas: 
SSAs can increase or reduce blood glucose concentrations, in insulinoma patients, depending on the 
SSTR pattern of expression on the insulinoma cells. Higher expression of SSTR2 in the insulinoma 
cells was associated with an improvement of hypoglycaemia in response to SSAs/octreotide; in 
contrast, low/absent expression of the receptor sub-type, SSTR2 in the insulinoma cells, is associated 
with paradoxical severe hypoglycaemia with SSA therapy, through suppression of glucagon and a 
short initial clinical trial of SSA is recommended.[24] 
Anti-proliferative effects The anti-proliferative effect of SSAs in the treatment of NETs was 
demonstrated in two major randomised, placebo-controlled studies: PROMID (octreotide LAR) and 
CLARINET (lanreotide) (Table 1, OSM).[25,26]  In PROMID, 85 patients with well differentiated 
midgut NETs were randomly assigned to receive octreotide LAR 30mg vs. placebo. Octreotide 
significantly prolonged time to progression (TTP) when compared with placebo (14.3 vs. 6 months; 
hazard ratio [HR], 0.34; 95% CI, 0.20 to 0.59; P<0.001); there was no difference in overall survival 
(OS). In CLARINET (n=204) patients with advanced gastroenteropancreatic NETs (GEP-NETs) treated 
with lanreotide autogel had improvement in progression free survival (PFS) when compared with 
placebo (PFS, not reached vs. 18 months and HR, 0.47; 95% Cl 0.30–0.73; P<0.001). Because of this 
anti-proliferative effect, SSAs may be considered first-line treatment in inoperable malignant 
insulinomas, capable of stabilising tumour growth in patients with metastatic insulinomas, although 
more information is needed on the duration and predictors of response.  
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3. OPTIONS FOR REFRACTORY CASES 
In patients with refractory insulinomas, whose symptoms have not responded to diazoxide or SSAs, 
there are several treatment options available. The optimal sequence for these treatments is 
unknown.  
 
3.1 Novel somatostatin analogues (Pasireotide) 
Mechanism of action Pasireotide is a novel multi-receptor somatostatin analogue that binds with 
high affinity to four somatostatin receptor subtypes (SSTR1, 2, 3, 5) (dubbed a ‘pan-receptor’ SSA). Its 
receptor binding affinity is 30-40 times higher for SSTR1 and SSTR5 than for octreotide.[27] The low 
expression of SSTR2 in many insulinomas, with malignant insulinomas in particular over-expressing 
SSTR5[28], may explain why conventional SSAs are ineffective and pasireotide becomes necessary. 
Already approved for the treatment of pituitary tumours associated with Cushing’s disease or 
acromegaly[27], pasireotide is not yet approved for the treatment of pNETs.  
Evidence to support pasireotide use in pNETS Several case reports have demonstrated the efficacy of 
pasireotide in the treatment of refractory hypoglycaemia in malignant insulinoma.[29,30] Future 
clinical trials are being designed to assess the anti-proliferative effects of pasireotide in NETs. 
Mechanism for the hyperglycaemic effects of pasireotide (Figure 2) Use of pasireotide in Cushing’s 
disease, acromegaly and in phase 2 studies in NETs (including pNETs) have highlighted significant 
hyperglycaemia (79%) and development of type 2 diabetes.[31] This adverse effect on glucose 
metabolism is welcomed in patients with insulinomas. Henry et al conducted an elegant study to 
determine the mechanism by which pasireotide causes hyperglycaemia, involving consecutive oral 
glucose tolerance tests (to measure serum glucose excursions), hyperglycaemic clamps (to 
determine pancreatic insulin secretion) and hyperinsulinaemic, euglycaemic clamps (to measure 
hepatic and peripheral insulin sensitivity) in healthy volunteers, given pasireotide 600, 900 and 1200 
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mcg b.d. for 7 days.[32] It was clearly demonstrated that hyperglycaemia is mediated by reduced 
pancreatic insulin secretion, a reduced incretin (both GLP1 and GIP) response but with unchanged 
peripheral (hepatic and peripheral insulin sensitivity). The greater hyperglycaemic effect of 
pasireotide, relative to octreotide or lanreotide, is explained by the different binding affinities of 
pasireotide to the different SSTR subtypes. The associated hyperglycaemia can be best managed 
with use of the anti-diabetic agents, vildagliptin and liraglutide.[33] 
 
3.2 Molecular targeted agents  
3.2.1  Everolimus (an mTOR receptor inhibitor)  
Mechanism of anti-proliferative effect mTOR inhibitors have an anti-proliferative effect by inhibiting 
signalling in the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway. Mammalian target of 
rapamycin (mTOR) is a serine/threonine kinase that is involved in the signal transduction response 
to insulin, growth factor and other nutrients via the phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway.[34] In patients with pNETs dysregulation of the Akt/mTOR pathway occurs, resulting in 
unrestrained cell growth, proliferation and reduced apoptosis.[35]  
Mechanism for the hyperglycaemic action of everolimus (Figure 3 and 4) The Akt/mTOR pathway is 
also involved in the control of glucose homeostasis and dysregulated mTOR signalling is implicated 
in peripheral insulin resistance through several distinct mechanisms: i) impaired skeletal muscle and 
adipose tissue glucose uptake via GLUT4 translocation, ii) impaired insulin-mediated suppression of 
hepatic gluconeogenesis and iii) impaired pancreatic beta-cell insulin secretion.[36] mTOR inhibition 
pharmacologically has a similar effect, resembling a state of peripheral insulin resistance.[37] 
Everolimus has also been shown to directly inhibit (pro)insulin secretion by insulinoma cells and this 
effect has been suggested from clinical experience.[37] Thus, everolimus as an mTOR inhibitor has 
an effect on tumour progression but will have secondary effects correcting hypoglycaemia.  
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Evidence to support everolimus use in pNETs Kulke was the first to report symptomatic relief of 
hypoglycaemia with everolimus[38] associated with a reduction in insulin levels with numerous 
subsequent case reports supporting this.[37,39]  
Efficacy and safety The efficacy and safety of everolimus in the treatment of NETs of 
different origins has been explored in the RADIANT trials (Table 2A, OSM).[40-42] In the 
phase 3 RADIANT-3 trial (RAD001 in Advanced Neuroendocrine Tumours) patients with 
advanced pancreatic NETs were randomised to receive everolimus, 10mg oral daily or 
placebo.[42]
 
 Everolimus prolonged progression-free survival (PFS) with PFS of 11 months 
with everolimus vs. 4.6 months in placebo patients (hazard ratio, 0.35; 95% confidence 
interval, 0.27-0.45; P <0.001). The response rate (RR) was 5% in the everolimus arm 
compared to 2% in the placebo arm, although significant side effects were noted. Bernard et 
al. retrospectively analysed the 12 insulinoma cases from the RADIANT-3 trial and noted the 
added benefit of improved glycaemic control in 11 out of the 12 patients treated with 
everolimus.[43] It must be highlighted that 3 patients discontinued everolimus because of 
cardiopulmonary adverse events. 2 patients were reported to have grade 4 pulmonary 
toxicity, leading to death in both cases, despite drug withdrawal. 
 
Side effects mTOR inhibitors demonstrate similar class-specific adverse effects, including rash, 
stomatitis, fatigue, hyperglycaemia and gastrointestinal upset. Generally these symptoms are 
manageable. Opportunistic infections and interstitial lung disease are adverse events of importance 
with potential significant morbidity and mortality. Guidelines for close lung surveillance have been 
published with baseline pre-treatment imaging recommended.[44] 
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Positioning in the clinical pathway Whereas tumour remissions are rare with everolimus, disease 
stabilisation is observed in a high proportion of patients (60-80%). Lack of head to head trials means 
that everolimus has mostly been used in advanced metastatic disease after the failure of SSAs 
and/or systemic chemotherapies and is generally reserved for progressive disease due to potential 
toxicities.  
 
3.2.2  Sunitinib (a tyrosine kinase inhibitor) 
Mechanism of action Sunitinib is an oral multi-targeted receptor tyrosine kinase inhibitor. Sunitinib 
displays anti-angiogenic and anti-tumour activity by inhibiting a number of molecular pathways 
involved in angiogenesis.[45]  
Evidence to support everolimus use in pNETs Previously approved for other malignancies (e.g. renal 
cell carcinomas and gastrointestinal stromal tumours) it has recently being approved for the 
treatment of advanced pNETs.[46,47] In a double-blind phase 3 trial, in 171 patients with 
progressive, low-grade or intermediate grade pNETs, sunitinib 37.5mg demonstrated impressive PFS 
benefits compared to placebo (Table 2B, OSM).[48] The trial was discontinued prematurely as 
sunitinib clearly offered improvements in PFS compared to placebo. Median PFS was 11.4 months in 
the sunitinib arm compared with 5.5 months in the placebo arm (hazard ratio, 0.42; 95% confidence 
interval, 0.26-0.66; P < 0.001). RRs in the sunitinib and placebo arms were 9.3% and 0% respectively. 
Unfortunately, only 2 patients receiving sunitinib had an insulinoma and the outcome of these 
particular patients was not described. Unlike everolimus this drug does not appear to have a direct 
action on glycaemic control.  
Side effects Cutaneous adverse events include mucositis, rash and hand–foot syndrome 
(HFS), characterised by palmar-plantar lesions. The most frequent side-effects reported 
include diarrhoea, nausea, vomiting, asthenia and fatigue. Hypertension and neutropenia are 
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the most frequent serious side-effects reported. Evidence suggests that sunitinib can worsen 
hypoglycaemia.[49]  
Positioning in the clinical pathway Despite the reported benefits of PFS in pNETs reported 
with sunitinib, the consequences of worsened hypoglycaemia may outweigh such benefits 
specifically in malignant insulinomas. 
 
3.3 Cytotoxic chemotherapy   
For patients with highly proliferating, rapidly progressive, and/or symptomatic pancreatic NETs, 
cytotoxic chemotherapy may yield greater tumour shrinkage than SSAs or molecularly targeted 
agents.  5-Fluourouracil (5-FU), doxorubicin and streptozocin have commonly been implicated in the 
treatment of inoperable malignant insulinomas.[50] Other agents (dacarbazine, cisplatin, etoposide, 
capecitabine and temozolamide) have also been evaluated. These combination treatments may help 
symptom control and have resulted in an objective response of 6-70% of patients with pNETs, 
however these studies included small numbers of insulinomas and a significant proportion of 
patients responded poorly with significant toxicity.[51-57] 
 
3.4 Loco-ablative and loco-regional techniques 
3.4.1 Ablative therapy 
Use of ablative therapy, either endoscopically directed or percutaneously, with radiological direction 
has also been reported to be successful. In recent years, EUS ethanol ablation has become a valuable 
alternative to surgical resection of primary disease. Under ultrasound guidance, introduction of 
ethanol directly into the tumour causes cell membrane lysis and necrosis.[58] The consequent 
destruction of the hypersecreting cells results in euglycaemia and amelioration of symptoms, the 
main aim of the procedure. The procedure is usually reserved for patients who are elderly, have 
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refused surgery, have high anaesthetic risk or in those with recurrent disease where reoperation is 
infeasible e.g. post-surgical fibrosis. It is best suited for single, small (1-2cm) pNET lesions that are 
not close to major blood vessels. 
Limited case-series and reports describe the use of ethanol ablation and describe a relatively strong 
safety profile with promising results in small, localised disease (Table 1).[59-66] Levy et al. reported 
the largest case series (8 patients) for ethanol ablation of insulinomas.[62] Five of those patients 
underwent EUS-guided ethanol injection and the remaining three underwent intra-operative 
ultrasound (IOUS)-guided ethanol injection. It was observed that the hypoglycaemic symptoms were 
relieved almost immediately post-procedure in all patients who underwent ethanol ablation and 
that this symptomatic relief was maintained throughout follow-up (range, 5–38 months). Currently 
there is no consensus as to the most appropriate volume and concentration of ethanol injection 
with potential intra-operator variability. With the risk of severe adverse events there is need to 
perform the technique in centres with good experience.  
Commonly reported complications from case reports include upper abdominal pain, localised 
bleeding and transient rises in lipase and amylase.[59-66] Severe adverse events such as pancreatitis 
have been reported in limited cases.[61] However the advantage is that it is a minimally invasive 
procedure, associated with a shorter hospital stay and is associated with a lower risk of 
complications. 
Further studies evaluating dosing and long-term follow-up in insulinomas are required. The major 
limitations of ethanol ablation are the possibility of late recurrence that would require retreatment, 
incomplete ablation, and the risk of progression during follow-up. Further literature is awaited to 
fully assess the long-term efficacy of ablation in a large RCT with longer follow-up of patients with 
localised disease. Its use in metastatic disease for symptom control only is also a possibility.[67]  
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3.4.2 Embolisation 
In patients with a large hepatic burden of disease, hepatic resection and hepatic artery embolisation 
(bland embolisation, chemo-embolisation, and radio-embolisation) may also be considered with the 
intention of ameliorating clinical symptoms. Selective embolisation of peripheral arteries induces 
temporary, but complete ischaemia.[68] Due to the small number of metastatic insulinomas there 
are no RCTs comparing loco-regional therapies, palliative liver surgery or medical management with 
limited case reports. Loco-regional procedures are most frequently used in combination with SSAs 
when surgery is not feasible. Systemic medical therapies or PRRT are often used preferentially, 
particularly in functioning pNETs (e.g. insulinomas) or when extrahepatic tumour load is greater than 
hepatic tumour burden. 
 
3.5 Nuclear medicine 
3.5.1  Peptide receptor radionuclide therapy (PRRT)  
Mechanism of action The use of peptide receptor radionuclide therapy (PRRT) depends on the 
binding of radiolabelled peptide hormones to the SSTRs on the tumour cell surface, with subsequent 
internalisation to deliver localised radiotherapy to the tumour cell with little effect on surrounding 
tissue. The most frequently used radio-peptides for targeted therapy include Yttrium (90Y) or 
Lutetium (177Lu) linked to a somatostatin analogue.[69] Prior to therapy, it is imperative to 
demonstrate expression of SSTRs on the tumour cells, hence a pre-treatment 111In-Octreotide or a 
Gallium68 DOTANOC PET-CT scan is performed. 
Evidence to support use of PRRT in pNETs Data from non-randomised trials of 177Lutetium-DOTATATE 
and 90Yttrium-DOTATOC, have consistently yielded impressive therapeutic benefits in patients with 
GEP-NETs, including pNETs.[70,71] NETTER-1 was the first large RCT of PRRT, comparing treatment 
with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care including octreotide LAR versus high-
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dose octreotide LAR (60mg every 4 weeks) in patients with inoperable, progressive, somatostatin 
receptor positive midgut neuroendocrine tumours (Table 3, OSM).[72] Treatment with 177Lu-
Dotatate resulted in markedly longer PFS and a significantly higher response rate than high-dose 
octreotide LAR among patients with advanced midgut neuroendocrine tumours. In this study, 
median PFS was 8 months on the high-dose octreotide arm and was not yet reached on the 177 Lu-
DOTATATE arm, translating to a 79% improvement in PFS (P <0.00001). Outcomes may be 
determined by patient characteristics including the amount of SSTR uptake at diagnosis[71] and 
tumour/liver burden.  
There have been two small case series of patients with metastatic insulinoma that have 
demonstrated that PRRT can control hyperinsulinaemic hypoglycaemia: euglycaemia persisted even 
in the face of tumour progression suggesting favourable symptomatic responses can be observed 
even with no objective evidence of tumour response.[39,73]  
Side effects PRRT is generally well tolerated. Acute side-effects are usually mild and include nausea 
and gastrointestinal upset. Importantly rare but serious side-effects may occur, including severe 
bone marrow disease (pancytopenia, acute myelogenous leukemia, myelodysplastic syndrome) and 
renal toxicity.[70,74] Another study of 265 patients undergoing PRRT found significant quality of life 
(QoL) improvements, regardless of treatment outcome.[75]  
Positioning in the clinical pathway In general, use of PRRT follows failed first‐line medical therapy 
(Figure 5). Positive somatostatin receptor positive disease is a prerequisite for starting treatment. 
PRRT offers a valuable treatment option for inoperable or metastatic pNETs, with promising 
responses and QoL improvements. In selected cases PRRT may be beneficial as a neoadjuvant 
therapy to render a patient accessible to surgery. There is need for RCTs in pNETs comparing PRRT 
to current best available treatment, including chemotherapy, everolimus and sunitinib. Moreover, 
data assessing dosing and the effectiveness of PRRT specifically in insulinoma patients is warranted. 
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4. CONCLUSIONS 
In sporadic insulinomas, surgical resection remains the primary treatment option. In the absence of 
surgical cure early referral to an experienced specialist neuroendocrine MDT is vital, so alternative 
treatments can be considered early to limit tumour growth and/or treat symptoms. A 
comprehensive review of the patient’s medical history, pathology, imaging and staging impacts upon 
therapy allocation.  
The publication of landmark studies (namely PROMID, CLARINET, RADIANT and NETTER-1) has been 
a significant development when considering therapeutic options for NETs, although have been 
performed in only small numbers with insulinomas. SSAs are typically used first line in patients with 
unresectable disease for control of symptoms and tumour growth. With disease progression, other 
medical therapies (e.g. pasireotide, everolimus, sunitinib) appear to be effective treatments for 
patients with metastatic disease and refractory hypoglycaemia although tolerance should be 
monitored carefully. In the case of pasireotide and everolimus these provide favourable effects on 
glucose concentrations in insulinoma patients, independent of a measurable tumour response. EUS-
guided ethanol ablation is technically feasible, allows targeted intervention and is relatively safe 
with good treatment responses in limited case reports of small localised disease, ideal for patients 
who refuse or are not eligible for surgery. Emerging therapeutic options undoubtedly offer the 
potential to improve patient outcomes and provide symptom control but sequence of therapy and 
efficacy and safety of therapy combinations remains an area for future research.  
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Table 1 Ultrasound guided ethanol ablation of sporadic insulinomas: case reports  
Authors et al. n Guidance Maximum 
diameter (mm) 
Total ethanol (mL) Ethanol (%) Complications 
Levy[62] 
5 EUS 8-20 0.1-3.0 95-99 None 
3 IOUS 11-12 0.7-1.5 95-98 
Pancreatitis, 
pseudocyst 
Qin[64] 4 EUS 5.4-11.8 0.25-0.5 95 None 
Paik[61] 3 EUS 9-14 1.2-3.0 99 Abdominal pain 
Trikudanathan[65] 1 EUS 14 1.0 - None 
Vleggar[66] 1 EUS 10 0.3 96 None 
Deprez [63] 1 EUS - 3.5 98 
Mild elevation 
pancreatic enzymes, 
haematoma 
Jurgensen[60] 1 EUS 13 8.0 95 
Abdominal pain, mild 
elevation pancreatic 
lipase 
Burghardt[59] 1 EUS 11 1.0 96 None 
EUS, endoscopic ultrasound; IOUS, intraoperative ultrasound; -, data not available 
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Figure 1 Treatment options for insulinomas 
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Figure 2 Pasireotide, a novel multi-receptor somatostatin analogue, acts predominantly via somatostatin receptor subtypes 2 and 5 and causes 
hyperglycaemia, through both DIRECT and INDIRECT effects.   
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Figure 3 Inhibition of mTOR by everolimus causes hyperglycaemia by several mechanisms synergistically: i) inducing peripheral (skeletal muscle and 
hepatic) insulin resistance through reduced Akt phosphorylation in skeletal muscle and liver respectively, ii) reducing beta cell insulin secretion, iii) 
reducing tumour cell proliferation by Akt-mediated inhibition of protein synthesis (Adapted from [76]). 
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Figure 4 Direct and indirect mechanism of action of everolimus in insulinoma 
18F-FDG-PET scanning demonstrate the A) reduced pathological tumour glucose uptake in liver and 
reduced physiological uptake in the muscles and myocardium during treatment with everolimus. B) 
Maximum standardised uptake values showing reduction in uptake in myocardium (solid, dark 
circles), forearm (open diamonds) and uptake in the hottest three tumour lesions averaged per 
patient (taken from [37]).  
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B) 
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Figure 5 A case of refractory insulinoma: a 58 year old taxi driver 
 
 
 
(A) CT abdomen pre-treatment. Large peripancreatic mass (9.6 x 3.7cm) with lymph node 
involvement, deemed inoperable. Histology from this tumour demonstrated a grade 2 pancreatic 
neuroendocrine tumour (Ki-67 10%).  Biochemical investigations confirmed endogenous 
hyperinsulinaemic hypoglycaemia (glucose 2.9 mmol/L, insulin 226 pmol/L and C-peptide 
1853pmol/L). 
(B) Gallium68 DOTANOC PET-CT. The large retroperitoneal irregular mass lesion demonstrates 
intense tracer uptake. The patient remained symptomatic with hypoglycaemia despite treatment 
with diazoxide and somatostatin analogues (sandostatin LAR 30mg). 
(C) CT abdomen 3 months post-treatment with everolimus. The mass lesion in the retroperitoneum 
had reduced in size (7.4 x 3.2 cm) associated with a good clinical response. Unfortunately, the 
patient developed a severe pneumonia requiring admission to intensive care. Everolimus was 
discontinued. 
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(D) MRI pancreas after 3 cycles of peptide receptor radionuclide therapy. The known 
peripancreatic retroperitoneal lobulated lesion has regressed in size (8 x 6.2 cm (11.3 x 6.4 cm 
immediately prior to PRRT)). There is still surrounding upper abdominal lymphadenopathy centred 
around the coeliac axis and head of the pancreas but the patient was asymptomatic. 
 
 
